Refocus Group, Inc.

Refocus Group's Mission is to Become a Surgical Standard of Care for Presbyopia, Primary Open-Angle Glaucoma and Ocular Hypertension Worldwide.

Welcome to Refocus Group Inc., a medical device company engaged in the research and development of treatments for human vision disorders. Refocus Group owns over 90 domestic and international pending applications and issued patents, the vast majority directed to methods, devices, and systems for the treatment of presbyopia, ocular hypertension, and primary open angle glaucoma.

Please note that Refocus Group's main products are part of the PresVIEW™ System which includes the PresVIEW™ Scleral Implant ("PSI"), and the PresVIEW™ Incision System, both of which are used to perform an innovative procedure called the PresVIEW™ Scleral Spacing Procedure ("SSP").

Please note that the company's primary product, the  PresVIEW™ Scleral Implant is an investigational device and is not yet approved for sale or use in the United States or Canada.  However, the product is currently approved for sale in the European Union.

Note: The PresVIEW™ SSP System for Presbyopia is an investigational device and is not yet approved for sale or use in the United States or Canada. The product is currently approved for sale in the European Union.

Note: At this time, the use of the PresVIEW™ SSP System for Glaucoma and Ocular Hyper Tension is only available within the European Union, where clinical trials are currently under way.